[HTML][HTML] What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …
[HTML][HTML] Effectiveness of an inactivated SARS-CoV-2 vaccine
A Wilder-Smith, K Mulholland - New England Journal of Medicine, 2021 - Mass Medical Soc
The world needs more vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), in order to …
(SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), in order to …
COVID-19 vaccines: implementation, limitations and opportunities
DD Richman - Global Health & Medicine, 2021 - jstage.jst.go.jp
The speed of development and the magnitude of efficacy of recently developed vaccines
directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize …
directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize …
Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities
Large-scale deployment of COVID-19 vaccines will seriously affect the ongoing phases 2
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …
and 3 randomised placebo-controlled trials assessing SARS-CoV-2 vaccine candidates …
Efficacy of COVID-19 vaccines: From clinical trials to real life
D Deplanque, O Launay - Therapies, 2021 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around
the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public …
the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public …
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization
MK Patel, I Bergeri, JS Bresee, BJ Cowling… - Vaccine, 2021 - Elsevier
Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints …
COVID-19 vaccines: concerns beyond protective efficacy and safety
Introduction Several vaccine candidates have been developed using different platforms,
including nucleic acids (DNA and RNA), viral vectors (replicating and non-replicating), virus …
including nucleic acids (DNA and RNA), viral vectors (replicating and non-replicating), virus …
[HTML][HTML] SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and
scientific expertise toward the goal of developing investigational vaccines to prevent COVID …
scientific expertise toward the goal of developing investigational vaccines to prevent COVID …
Lead SARS-CoV-2 candidate vaccines: expectations from phase III trials and recommendations post-vaccine approval
E Tumban - Viruses, 2020 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted primarily
through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial …
through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial …
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials
JA Singh, REG Upshur - The Lancet Infectious Diseases, 2021 - thelancet.com
An efficacious COVID-19 vaccine is currently the world's leading research priority. Several
nations have indicated that if there is a compelling case for use of a vaccine before it is …
nations have indicated that if there is a compelling case for use of a vaccine before it is …